Kezar Life Sciences, Inc. (KZR) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 South San Francisco, CA, 美国. 现任CEO为 Christopher J. Kirk.
KZR 拥有 IPO日期为 2018-06-21, 55 名全职员工, 在 NASDAQ Global Select, 市值为 $54.4M.
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
